Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024
Krystal Biotech (NASDAQ: KRYS), a commercial-stage biotechnology company, has announced it will release its second quarter 2024 financial results on August 5, 2024, before U.S. markets open. The company's management will host a conference call and webcast at 8:30 am ET on the same day to discuss the results and provide a business update.
Investors and the public can access the live webcast at a provided link. For those unable to attend, a replay will be available for 30 days on the company's website. This announcement indicates Krystal Biotech's commitment to transparency and shareholder communication, as it prepares to share its latest financial performance and operational progress.
Krystal Biotech (NASDAQ: KRYS), una società biotecnologica in fase commerciale, ha annunciato che rilascerà i suoi risultati finanziari del secondo trimestre 2024 il 5 agosto 2024, prima dell'apertura dei mercati statunitensi. La direzione dell'azienda ospiterà una call e webcast alle 8:30 ET lo stesso giorno per discutere i risultati e fornire un aggiornamento sull'andamento aziendale.
Gli investitori e il pubblico possono accedere al webcast in diretta tramite un link fornito. Per coloro che non possono partecipare, una registrazione sarà disponibile per 30 giorni sul sito web dell'azienda. Questo annuncio indica l'impegno di Krystal Biotech per la trasparenza e la comunicazione con gli azionisti, mentre si prepara a condividere le ultime performance finanziarie e i progressi operativi.
Krystal Biotech (NASDAQ: KRYS), una empresa de biotecnología en etapa comercial, ha anunciado que dará a conocer sus resultados financieros del segundo trimestre de 2024 el 5 de agosto de 2024, antes de la apertura de los mercados en EE. UU. La dirección de la empresa llevará a cabo una llamada y webcast a las 8:30 am ET el mismo día para discutir los resultados y proporcionar una actualización sobre el negocio.
Los inversores y el público pueden acceder a la transmisión en vivo a través de un enlace proporcionado. Para aquellos que no puedan asistir, una repetición estará disponible durante 30 días en el sitio web de la empresa. Este anuncio indica el compromiso de Krystal Biotech con la transparencia y la comunicación con los accionistas, mientras se prepara para compartir su último rendimiento financiero y avances operativos.
Krystal Biotech (NASDAQ: KRYS)는 상업 단계에 있는 생명공학 회사로서 2024년 2분기 재무 결과를 2024년 8월 5일에 미국 시장 개장 전에 발표할 것이라고 발표했습니다. 회사의 관리팀은 같은 날 동부 표준시 기준 오전 8시 30분에 결과를 논의하고 사업 업데이트를 제공하기 위해 컨퍼런스 콜 및 웹캐스트를 진행합니다.
투자자와 대중은 제공된 링크를 통해 실시간 웹캐스트에 접속할 수 있습니다. 참석할 수 없는 분들을 위해, 30일 동안 다시 보기 서비스가 회사 웹사이트에 제공됩니다. 이 발표는 Krystal Biotech가 최신 재무 성과 및 운영 진행 상황을 공유하기 위해 투명성과 주주 소통에 전념하고 있음을 나타냅니다.
Krystal Biotech (NASDAQ: KRYS), une entreprise de biotechnologie en phase commerciale, a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre 2024 le 5 août 2024, avant l'ouverture des marchés américains. La direction de l'entreprise animera une conférence téléphonique et une diffusion en direct à 8h30 HE le même jour pour discuter des résultats et fournir une mise à jour sur l'activité.
Les investisseurs et le public peuvent accéder à la diffusion en direct via un lien fourni. Pour ceux qui ne peuvent pas assister, une rediffusion sera disponible pendant 30 jours sur le site Web de l'entreprise. Cette annonce témoigne de l'engagement de Krystal Biotech envers la transparence et la communication avec les actionnaires, alors qu'elle se prépare à partager ses dernières performances financières et ses progrès opérationnels.
Krystal Biotech (NASDAQ: KRYS), ein biotechnologisches Unternehmen in der kommerziellen Phase, hat bekannt gegeben, dass es seine finanzielle Ergebnisse für das zweite Quartal 2024 am 5. August 2024, vor der Öffnung der US-Märkte, veröffentlichen wird. Das Management des Unternehmens wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz und ein Webcast veranstalten, um die Ergebnisse zu diskutieren und ein Geschäftsupdate zu geben.
Investoren und die Öffentlichkeit können über einen bereitgestellten Link auf den Live-Webcast zugreifen. Für diejenigen, die nicht teilnehmen können, wird eine Wiederholung für 30 Tage auf der Unternehmenswebsite verfügbar sein. Diese Ankündigung zeigt das Engagement von Krystal Biotech für Transparenz und Kommunikation mit den Aktionären, während das Unternehmen sich darauf vorbereitet, seine neuesten finanziellen Leistungen und betrieblichen Fortschritte zu teilen.
- Timely reporting of quarterly financial results
- Hosting a conference call and webcast for investors and public
- Providing a 30-day replay option for the webcast
- None.
PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its second quarter 2024 financial results on Monday, August 5, 2024, prior to the open of U.S. markets.
The Company’s management will also host a conference call and webcast at 8:30 am ET on Monday, August 5, 2024, to discuss the financial results and provide a business update.
Investors and the general public can access the live webcast at: https://www.webcaster4.com/Webcast/Page/3018/50830.
For those unable to listen to the live webcast, a replay will be available for 30 days on the Investors section of the Company’s website at www.krystalbio.com.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).
CONTACT
Investors and Media:
Stéphane Paquette, PhD
Krystal Biotech
spaquette@krystalbio.com
FAQ
When will Krystal Biotech (KRYS) report its Q2 2024 financial results?
What time is Krystal Biotech's (KRYS) Q2 2024 earnings call scheduled for?
How can investors access Krystal Biotech's (KRYS) Q2 2024 earnings webcast?
For how long will the replay of Krystal Biotech's (KRYS) Q2 2024 earnings call be available?
